*Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital; †School of Medical Sciences, University of New South Wales; ‡Department of Chemical Pathology, St Vincent's Hospital; and §St Vincent's Clinical School, University of New South Wales, Sydney, Australia.
Ther Drug Monit. 2013 Dec;35(6):863-6. doi: 10.1097/FTD.0b013e318299920a.
Oxypurinol, the active metabolite of allopurinol, is the major determinant of the hypouricemic effect of allopurinol. Monitoring oxypurinol concentrations is undertaken to determine adherence to therapy, to investigate reasons for continuing attacks of acute gout and/or insufficiently low plasma urate concentrations despite allopurinol treatment, and to assess the risk of allopurinol hypersensitivity, an adverse effect that has been putatively associated with elevated plasma oxypurinol concentrations.
An audit of request forms requesting plasma oxypurinol concentration measurements received by the pathology service (SydPath) at St Vincent's Hospital, Darlinghurst, Sydney was undertaken for the 7-year period January 2005-December 2011. Patient demographics, biochemical data, including plasma creatinine and uric acid concentrations, comorbidities, and concomitant medications were recorded.
There were 412 requests for determination of an oxypurinol concentration. On 48% of occasions, the time of allopurinol dosing was recorded, while just 79 (19%) blood samples were collected 6-9 hours postdosing, the time window used to establish the therapeutic range for oxypurinol. For these optimally interpretable concentrations, 32 (8%) were within the putative therapeutic range (5-15 mg/L), while 5 (1%) were below and 41 (10%) above this range. The daily dose of allopurinol was documented on only one-third of the request forms. Individually, plasma urate and creatinine concentrations were requested concomitantly with plasma oxypurinol concentrations in 66% and 58% of the cases, respectively; while plasma oxypurinol, urate, and creatinine concentrations were requested concomitantly in 49% of the cases.
Requesting clinicians and blood specimen collectors often fail to provide relevant information (dose, times of last dose, and blood sample collection) to allow the most useful interpretation of oxypurinol concentrations. Concomitant plasma urate and creatinine concentrations should be requested to allow more complete interpretation of the data.
别嘌醇的活性代谢物氧嘌呤醇是别嘌醇降血尿酸作用的主要决定因素。监测氧嘌呤醇浓度可用于确定治疗依从性,调查尽管接受别嘌醇治疗仍持续发作急性痛风和/或血尿酸浓度不足的原因,以及评估别嘌醇过敏反应的风险,别嘌醇过敏反应是一种不良作用,据称与血浆氧嘌呤醇浓度升高有关。
对 2005 年 1 月至 2011 年 12 月期间在悉尼达令赫斯特圣文森特医院病理科(SydPath)收到的请求测定血浆氧嘌呤醇浓度的申请表格进行了审核。记录了患者的人口统计学资料、生化数据,包括血浆肌酐和尿酸浓度、合并症和同时使用的药物。
共收到 412 份测定氧嘌呤醇浓度的申请。在 48%的情况下,记录了别嘌醇给药时间,而只有 79(19%)份血样是在给药后 6-9 小时采集的,这是确定氧嘌呤醇治疗范围的时间窗。对于这些可最佳解释的浓度,32(8%)在假定的治疗范围内(5-15mg/L),5(1%)低于该范围,41(10%)高于该范围。只有三分之一的申请表格记录了别嘌醇的日剂量。单独来看,在 66%和 58%的情况下,分别同时请求了血浆尿酸和肌酐浓度,而在 49%的情况下,同时请求了血浆氧嘌呤醇、尿酸和肌酐浓度。
请求的临床医生和血液标本采集者经常未能提供相关信息(剂量、最后一次给药时间和血液样本采集时间),无法对氧嘌呤醇浓度进行最有用的解释。应同时请求测定血浆尿酸和肌酐浓度,以更全面地解释数据。